IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v40y2022i2d10.1007_s40273-022-01222-x.html
   My bibliography  Save this article

Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L

Author

Listed:
  • Jonathan L. Nazari

    (University of Illinois Chicago)

  • A. Simon Pickard

    (University of Illinois Chicago)

  • Ning Yan Gu

    (University of San Francisco)

Abstract

Objectives The International Valuation Protocol for the valuation of the EQ-5D-Y-3L provides baseline guidance, but country-specific context is also important. This study aimed to obtain US stakeholders’ input on key considerations for youth valuation in the US. Methods A total of 14 stakeholders representing various backgrounds were identified via the investigators’ networks. A 2-h online meeting was held to discuss (1) the need for a US value set for the EQ-5D-Y-3L; (2) willingness to pay more for quality-adjusted life-year (QALY) gains for children versus adults; (3) sampling strategies; (4) framing perspectives; and (5) other challenges. The session was recorded, transcribed, and summarized. Results Several stakeholders supported paying more for QALY gains for children in recognition of their potential future contributions to society, as well as to avoid potential undervaluation and promote access to innovative treatments. Concerns regarding possible double counting, lack of data to showcase long-term benefits, and dangers of paying more for certain subgroups were also expressed. Most of the stakeholders felt that adolescents could relate to a 10-year-old’s perspective better than adults and were capable of self-completing valuation tasks, and thus should be directly included in the valuation study. There were concerns that adults would be inconsistent in their views about a 10-year-old, partly depending on their status as a parent. Conclusions US stakeholders provided insights relevant to youth valuation in a US context and were open to continued dialogue with investigators. This study could be useful to investigators who are conducting youth valuation studies in different countries and seeking stakeholder input.

Suggested Citation

  • Jonathan L. Nazari & A. Simon Pickard & Ning Yan Gu, 2022. "Findings from a Roundtable Discussion with US Stakeholders on Valuation of the EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 139-146, December.
    • Handle: RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-022-01222-x
    DOI: 10.1007/s40273-022-01222-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-022-01222-x
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-022-01222-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Fanni Rencz & Gábor Ruzsa & Alex Bató & Zhihao Yang & Aureliano Paolo Finch & Valentin Brodszky, 2022. "Value Set for the EQ-5D-Y-3L in Hungary," PharmacoEconomics, Springer, vol. 40(2), pages 205-215, December.
    2. Simone Kreimeier & David Mott & Kristina Ludwig & Wolfgang Greiner, 2022. "EQ-5D-Y Value Set for Germany," PharmacoEconomics, Springer, vol. 40(2), pages 217-229, December.
    3. Bram Roudijk & Ayesha Sajjad & Brigitte Essers & Stefan Lipman & Peep Stalmeier & Aureliano Paolo Finch, 2022. "A Value Set for the EQ-5D-Y-3L in the Netherlands," PharmacoEconomics, Springer, vol. 40(2), pages 193-203, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Powell, Philip A. & Rowen, Donna & Keetharuth, Anju & Mukuria, Clara, 2024. "Understanding UK public views on normative decisions made to value health-related quality of life in children: A qualitative study," Social Science & Medicine, Elsevier, vol. 340(C).
    2. Nancy Devlin & Bram Roudijk & Rosalie Viney & Elly Stolk, 2022. "EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions," PharmacoEconomics, Springer, vol. 40(2), pages 123-127, December.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Zhihao Yang & Jie Jiang & Pei Wang & Xuejing Jin & Jing Wu & Yu Fang & Da Feng & Xiaoyu Xi & Shunping Li & Mingxia Jing & Bin Zheng & Weidong Huang & Nan Luo, 2022. "Estimating an EQ-5D-Y-3L Value Set for China," PharmacoEconomics, Springer, vol. 40(2), pages 147-155, December.
    2. David J. Mott & Nancy J. Devlin & Simone Kreimeier & Richard Norman & Koonal K. Shah & Oliver Rivero-Arias, 2022. "Analytical Considerations When Anchoring Discrete Choice Experiment Values Using Composite Time Trade-Off Data: The Case of EQ-5D-Y-3L," PharmacoEconomics, Springer, vol. 40(2), pages 129-137, December.
    3. Sarah Dewilde & Bram Roudijk & Nafthali H. Tollenaar & Juan M. Ramos-Goñi, 2022. "An EQ-5D-Y-3L Value Set for Belgium," PharmacoEconomics, Springer, vol. 40(2), pages 169-180, December.
    4. Nancy Devlin & Bram Roudijk & Rosalie Viney & Elly Stolk, 2022. "EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions," PharmacoEconomics, Springer, vol. 40(2), pages 123-127, December.
    5. Fanni Rencz & Gábor Ruzsa & Alex Bató & Zhihao Yang & Aureliano Paolo Finch & Valentin Brodszky, 2022. "Value Set for the EQ-5D-Y-3L in Hungary," PharmacoEconomics, Springer, vol. 40(2), pages 205-215, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:40:y:2022:i:2:d:10.1007_s40273-022-01222-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.